Cite
MLA Citation
Jonathan S Cebon et al.. “Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.” Journal for immunotherapy of cancer, vol. 8, no. 1, 2020, p. . http://access.bl.uk/ark:/81055/vdc_100127569687.0x000033